D&D Pharmatech reported positive phase 2 results for DD01, a dual GLP-1/glucagon receptor agonist, demonstrating significant reductions in liver fat—over 30% in 75.8% of treated patients—and encouraging weight loss in patients with metabolic dysfunction-associated steatohepatitis (MASH). The 12-week trial showed better outcomes compared to placebo, with generally manageable gastrointestinal side effects. These findings add to growing interest in GLP-1 therapies for MASH, following advances by Novo Nordisk and Eli Lilly, spotlighting DD01 as a promising candidate for metabolic liver disease management.